Skip to main content
. 2022 Nov 17;128(2):266–274. doi: 10.1038/s41416-022-02050-8

Fig. 4. Matched baseline-residual disease TILs level in the overall and anthracycline + taxane (AT) + /− Carboplatin (AT-Cb) population.

Fig. 4

a Matched baseline-residual disease TIL level in the overall and anthracycline + taxane (AT) + /− Carboplatin (AT-Cb) population. b Matched baseline-residual disease TIL levels in the subgroup of patients with low baseline TILs. Data were analysed by Wilcoxon non-parametric test.